mRNA vaccines, like those developed for COVID-19, offer rapid design, high efficacy (e.g., Moderna's flu vaccine showed 26.6% higher efficacy than standard shots in adults 50+), and adaptability to new variants by using genetic code to instruct cells to produce antigens.